60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Ticker SymbolSXTPW
Company name60 Degrees Pharmaceuticals Inc
IPO dateJul 12, 2023
CEODr. Ll S. Dow, Ph.D.
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address1025 Connecticut Avenue Nw
CityWASHINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code20036
Phone12023275422
Websitehttps://60degreespharma.com/
Ticker SymbolSXTPW
IPO dateJul 12, 2023
CEODr. Ll S. Dow, Ph.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data